

por lo que su manejo debe ser multidisciplinar. Es de suma importancia el papel del neumólogo en el seguimiento de estos pacientes, siendo necesario realizar pruebas funcionales de forma reglada tras el TPH, así como estudios radiológicos y microbiológicos si presentan síntomas respiratorios, con el objetivo de diagnosticar y tratar precozmente la BO.

## Bibliografía

- Williams K, Chien J, Gladwin J, Pavletic S. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. *JAMA*. 2009;302:306–14.
- Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. *N Engl J Med*. 2014;370:1820–8.
- Rhee C, Ha J, Yoon J, Cho B, Min WS. Risk factor and clinical outcome of bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. *Yonsei Med J*. 2016;57:365–72.
- Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes. *Biol Blood Marrow Transplant*. 2003;9:657–66.
- Gronningsaeter I, Tsykunova G, Lilleeng K, Bushra A, Bruserud O, Reikvam H. Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation—pathophysiology, diagnostics and treatment. *Expert Rev Clin Immunol*. 2017;13:553–69.
- Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation—an increasingly recognized manifestation of chronic graft-versus-host disease. *Biol Blood Marrow Transplant*. 2010;16 Suppl 1:S106–14.
- Chien JW. Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. *Expert Rev Respir Med*. 2011;5:127–35.
- Kwok WC, Liang BM, Lui MMS, Tam TCC, Sim JPY, Tse EWC, et al. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome. *Respirology*. 2019;24:459–66. <http://dx.doi.org/10.1111/resp.13472>.
- Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: Updated consensus recommendations of the European Society for Blood and Marrow Transplantation. *Lancet Haematol*. 2020;7:e157–67. [http://dx.doi.org/10.1016/S2352-3026\(19\)30256-X](http://dx.doi.org/10.1016/S2352-3026(19)30256-X).

Adrián Martínez-Vergara<sup>a,\*</sup>, Rosa M. Girón<sup>a</sup>,  
María Churruca-Arróspide<sup>a</sup>, Patricia López-Pereira<sup>b</sup>,  
Elena Sola-Aparicio<sup>b</sup> y Beatriz Aguado-Bueno<sup>b</sup>

<sup>a</sup> Servicio de Neumología, Hospital de La Princesa, Madrid, España

<sup>b</sup> Servicio de Hematología, Hospital de La Princesa, Madrid, España

\* Autor para correspondencia.

Correo electrónico: [martinezvadrian@gmail.com](mailto:martinezvadrian@gmail.com)  
(A. Martínez-Vergara).

<https://doi.org/10.1016/j.arbres.2020.12.012>

0300-2896/ © 2020 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Non-Invasive Ventilation for Acute Respiratory Failure in Duchenne Muscular Dystrophy Patients



### Ventilación no invasiva para la insuficiencia respiratoria aguda en pacientes con distrofia muscular de Duchenne

Dear Editor:

Duchenne Muscular Dystrophy (DMD) is the most common inherited muscle disease in children, with a prevalence ranging between 1.3 and 2.1 per 10,000 live male births.<sup>1</sup> Acute Respiratory Failure (ARF) is a common complication in individuals with DMD and a primary cause of mortality, both in the teenage and adult years.<sup>2</sup>

Non-Invasive Ventilation (NIV) is a ventilatory technique for delivering pressurized gas to the lungs through a sealed mask that can be placed over the mouth, nose or the whole face; its utilization is recommended for the management of ARF across a variety of aetiologies. However, NIV application in exacerbated DMD patients is still controversial and not indicated by major guidelines.<sup>3</sup> The aim of our study was to evaluate clinical status and outcomes in DMD patients being administered NIV for ARF.

We collected and reviewed all of the medical records of the DMD patients with ARF who were admitted to our adult 4 bed Respiratory ICU (RICU) at the University of Padua Medical Center between January 1, 2005 and December 31, 2019. Ethical approval was waived by the local Ethics Committee in view of the fact that the study was retrospective and not prepared according to a research project.

At the time of admission to the RICU, the clinical and physiologic parameters of these patients were consistent with ARF. In particular, each of them presented at least one of the following: (1) respiratory distress; (2) hypoxemia and/or hypercapnia; (3) acute

respiratory acidosis.<sup>4</sup> Patients who had received NIV as first-line ventilatory treatment were included in the study; those who had a tracheostomy tube in place or showed an immediate need for Endotracheal Intubation (ETI)<sup>5</sup> were excluded.

All hospital charts were reviewed for patients' baseline clinical, demographic and pulmonary function data after informed consent release forms were obtained. Clinical, laboratory and blood gas data at RICU admission were also recorded and analyzed.

Causes of ARF were classified as: upper respiratory tract infection (URTI); acute decompensated heart failure (ADHF); pneumonia; and other (e.g., pneumothorax, pulmonary thromboembolism, dysphagia with aspiration, gastroparesis/malnutrition, acute gastrointestinal distension, abuse of sedatives). The diagnosis of URTI was based on the presence of one or more of the following symptoms or signs: fever, throat irritation or sore throat, hoarseness<sup>6</sup>; the diagnoses of pneumonia and/or ADHF were based on major guidelines.<sup>7,8</sup>

The decision to begin NIV was usually made by the attending physician, according to the hospital internal protocol.<sup>9</sup> NIV was usually delivered using a portable ventilator set in assisted pressure-control ventilation (APCV) mode. A commercial full-face mask was used when NIV was initiated and in some cases it was substituted by a nasal mask after the first hours of ventilation. In the event of NIV failure, the patients were shifted from NIV to Invasive Mechanical Ventilation (IMV) by ETI unless they had previously declared that they did not wish to be intubated. Mechanical In-Exsufflation (MI-E) was usually administered to those patients showing bronchial mucous encumbrance and oxyhemoglobin desaturation secondary to secretion retention, according to the hospital internal protocol.<sup>6</sup> The patients were divided into 2 groups depending on their NIV response. "NIV success group" was made up of those individuals who avoided ETI, were discharged from RICU and survived for at least 48 h after being

**Table 1**  
Patients' baseline demographic, clinical, and cardio-pulmonary function characteristics, and clinical, laboratory and blood gas data at RICU admission.

	All cases	NIV succes group	NIV failure group	p-Value
<b>Baseline demographic, clinical and cardio-pulmonary function data</b>				
<i>Number of subjects</i>	42	36(85.7%)	6(14.3%)	NA
Age (years), median (range)	23.5 (2–41)	24.5 (14–41)	15 (14–30)	0.0201
BMI (kg/m <sup>2</sup> ), median (range)	21.1 (9.5–35.2)	21.1 (9.5–35.2)	20.7 (14.7–28.5)	0.9615
Age at DMD diagnosis (years), median (range)	5 (0.3–11)	5 (0.3–11.0)	0.7 (0.7–0.7)	0.1932
Pts with scoliosis, N (%)	37(88.1)	33(91.7)	4(66.7)	0.1414
Pts with cardiomyopathy, N (%)	19(45.2)	17(47.2)	2(33.3)	0.6729
Pts with a history of constipation, N (%)	10(23.8)	9(25.0)	1(16.7)	0.9999
Pts undergoing long-term NIV, N (%)	19(45.2)	17(47.2)	2(33.3)	0.6729
Pts previously administered PEG, N (%)	6(14.3)	5(13.9)	1(16.7)	0.9999
FVC (L), median (range)	0.86 (0.11–1.98)	0.85 (0.11–1.98)	0.96 (0.30–1.47)	0.8967
FVC (%), median (range)	16.0 (3.0–96.0)	15.0 (3.0–96.0)	22.0 (9.0–32.0)	0.9501
MIP (cm H <sub>2</sub> O), median (range)	23(8–37)	23(8–37)	–	NA
MEP (cm H <sub>2</sub> O), median (range)	20(4–30)	20(4–30)	–	NA
<i>Clinical, laboratory and blood gas data at RICU admission</i>				
Heart rate (beats/min), median (range)	108.5 (45.0–134.0)	104.0 (45.0–112.0)	123.0 (120.0–134.0)	0.0095
Respiratory rate (breaths/min), median (range)	14.0 (12.0–18.0)	14.0 (12.0–18.0)	14.0 (12.0–16.0)	0.8390
Pts with fever, N (%) (Temperature >38 °C)	3(7.1)	3(8.3)	0(0.0)	0.9999
Total WBC count (×10 <sup>9</sup> /L), median (range)	8.82 (2.06–18.02)	8.65 (2.06–18.02)	13.2 (11.06–17.80)	0.0113
Pts with abnormal CRP or ESR level, N (%)	15(35.7)	14(38.9)	1(16.7)	0.5085
PaO <sub>2</sub> * (mmHg), median (range)	71.6 (33.8–175)	70.6 (43.1–105.8)	92.8 (33.8–175)	0.2123
PaCO <sub>2</sub> (mmHg), median (range)	44.7 (31.6–96.1)	44.6 (32–78)	52.8 (31.6–96.1)	0.5949
Arterial pH, median (range)	7.4 (7.3–7.6)	7.4 (7.3–7.6)	7.4 (7.3–7.5)	0.8698
SaO <sub>2</sub> (%), median (range)	95.5 (88.9–99.2)	95.1 (88.9–99)	98 (94.8–99.2)	0.0110
Pts with abnormal BNP or NT-proBNP level, N (%)	13(30.9)	12(33.3)	1(16.7)	0.6468
Pts with hypokalemia, N (%)	12(28.6)	10(27.7)	2(33.3)	0.9999

BMI = Body Mass Index; BNP = Brain Natriuretic Peptide; CRP = C-Reactive Protein; DMD = Duchenne Muscular Dystrophy; ESR = Erythrocyte Sedimentation Rate; FVC = Forced Vital Capacity; MEP = Maximal Expiratory Pressure; MIP = Maximal Inspiratory Pressure; NA = not applicable; NIV = Non-Invasive Ventilation; NT-proBNP = N-terminal pro-hormone of Brain Natriuretic Peptide; PEG = Percutaneous gastrostomy; RICU = Respiratory Intensive Care Unit; SaO<sub>2</sub> = arterial oxygen saturation; WBC = White Blood Cell.  
p-Values refer to differences between NIV success and NIV failure groups.

\* During supplemental oxygen therapy.

transferred to the respiratory ward. “NIV failure group” was made up of those subjects who required ETI or died while on NIV support.

During the study period, 51 patients were admitted to our RICU for ARF with a primary diagnosis of DMD. Seven (13.7%) had a tracheostomy tube in place and were administered IMV via tracheal cannula, 2 (3.9%) were intubated at admission, while all the remaining 42 (82.3%), received NIV as the first-line ventilatory intervention and were considered eligible to participate in our retrospective study. No patient experienced repeated episodes of ARF. Of notice, RICU admissions were evenly distributed during the study period. Baseline demographic, clinical, pulmonary and cardiac function, of the patients are outlined in Table 1. Conditions associated with the onset of ARF in the patients studied included URTI (19 cases); ADHF (5 cases); pneumonia (4 cases); and other conditions (14 cases). The patients were administered NIV in APCV. The initial inspiratory pressure above PEEP was 12 (8–25) cmH<sub>2</sub>O. All subjects were fully cooperative during NIV and did not require any sedation. NIV was successful in 36 patients (85.7%), while unsuccessful in the remaining 6 (14.3%). The median time from NIV initiation to intubation was 3.5 (1–11) days. Among patients who failed NIV, the cause of ARF was dysphagia with aspiration in 3 cases; ADHF in 2 cases; and pneumonia in 1 case. Causes of NIV failure were failure to adequately correct hypercapnia and exhaustion (3 cases), persistent accumulation of bronchial secretions (2 cases), and severe hemodynamic instability (1 case). Two patients died following intubation while on IMV support; the remaining four required tracheostomy due to difficult weaning and underwent long-term invasive ventilation. No major NIV complication was observed, while minor complications occurred in 4 patients (nasal skin lesions in 3 cases and acute bowel distension in 1 case). All 36 patients successfully treated and 4 out of 6 who failed NIV were discharged alive from hospital. Patients' characteristics at RICU admission are outlined in Table 1. The median survival of the 42 NIV patients after RICU admission was 67.1 (95%CI, 15.0 to 125.4) days.

Survival was significantly reduced for patients who failed NIV, compared to those who succeeded [median survival time: 11.7 (95%CI, 0.0 to 131.0) vs 85.9 (95%CI, 24.9 to 125.4) days], with an HR of dying of 3.91 (95%CI, 1.10 to 13.93;  $p=0.0351$ ). None of the covariates had a significant effect on NIV failure. However, patients who did not respond to NIV were younger than those who succeeded [15 (14–30) vs. 24.5 (14–41) yrs;  $p=0.0201$ ]; moreover, patients' characteristics at RICU admission showed greater HR values [123.0 (120.0–134.0) vs. 104.0 (45.0–112.0) b/min;  $p=0.0095$ ], total WBC count [13.2 (11.06–17.80) vs. 8.65 (2.06–18.02);  $p=0.0113$ ] and SaO<sub>2</sub> [98 (94.8–99.2) vs. 95.1 (88.9–99);  $p=0.0111$ ] for failures, as opposed to successes (Table 1).

The use of NIV in DMD patients for ARF is still debated.<sup>10–12</sup> In our study, the overall success rate of 86% corroborates the positive role of NIV in avoiding tracheal intubation. On our opinion, high success rate of NIV treatment in our patients can be explained by several factors, including the following. First, we used APCV, a mode of partial ventilatory support found to be comfortable and minimally affected by patient-ventilator asynchrony in individuals with ventilatory failure of neuromuscular origin.<sup>13</sup> Second, we chose full-face mask as first choice. Indeed, nasal masks may be problematic in these patients because of weakness of masseter muscles, causing incomplete jaw closing and major mouth air leaks. Furthermore, patients with ARF are characterized by mouth-breathing making nasal masks ineffective. For these reasons, despite a potentially increased risk of gastric distension and emesis into the mask,<sup>14</sup> a full face mask was preferred in our patients. Third, the combined use of MI-E was effective in clearing bronchial secretions in most patients who developed bronchial mucous encumbrance and consequent oxyhemoglobin desaturation, in keeping with previous data both in adults and children with NMD.<sup>15</sup> Finally, it is worth remarking that our team of pulmonary physicians and nurses has been involved in NIV treatment of NMD patients with ARF for over 20 years.

Notwithstanding the low NIV failure rate, we believe that appropriate selection criteria for attempting NIV in this setting is a crucial unresolved issue. Unfortunately, we found none of the covariates associated with NIV failure. Noteworthy, patients who did not respond to NIV were younger than those who succeeded and reported dysphagia, weight loss and aspiration in 3 out of 6 cases. Swallowing disturbances resulting in increased risk of inhalation have been reported as a possible mechanism of ARF in boys with DMD<sup>16</sup> and a common cause of NIV failure in NMD patients.<sup>9</sup>

Of interest, there was a trend toward higher PaO<sub>2</sub>, SaO<sub>2</sub>, and PaCO<sub>2</sub> values in the NIV failure compared to NIV success group. We hypothesize that delivery of excessively high amounts of supplemental oxygen during transfer to our RICU might have increased the risk of NIV failure, by depressing spontaneous ventilation. Indeed, oxygen therapy has been shown to reduce the drive to breathe and lead to CO<sub>2</sub> retention in DMD patients during respiratory exacerbations.<sup>17</sup>

Our study has important limitations, being single-centered, retrospective and observational. It is important to remind, however, that prospective randomized trials in this patient population are unlikely to be performed because of the limited number of patients affected with DMD and of possible ethical issues. The study's long time span is also a potential weakness. Worth mentioning, however, we did not make significant changes in pharmacologic therapy and/or supportive care during the study period.

Despite these major limitations, our study indicates NIV to be a viable option in DMD patients showing signs of ARF as it can effectively reverse ARF in the majority of patients, with the caveat that its use should be extremely careful in younger patients with dysphagia.

## Bibliografía

- Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, et al. Prevalence of Duchenne and Becker muscular dystrophies in the United States. *Pediatrics*. 2015;135:11.
- Van Ruiten HJA, Marini Bettolo C, Cheetham T, Eagle M, Lochmuller H, Straub V, et al. Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England. *Eur J Paediatr Neurol*. 2016;20:904–9.
- Rochweg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *Eur Respir J*. 2017;50:1602426.
- Meduri GU, Conoscenti CC, Menashe P, Nair S. Noninvasive face mask ventilation in patients with acute respiratory failure. *Chest*. 1989;95:865–70.
- American Thoracic Society, European Respiratory Society, European Society of Intensive Care Medicine, Société de Réanimation de Langue Française. International Consensus Conference in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Approved by the ATS Board of Directors, December 2000. *Am J Respir Crit Care Med*. 2001;163:283–91.
- Vianello A, Corrado A, Arcaro G, Gallan F, Ori C, Minuzzo M, et al. Mechanical insufflation-exsufflation improves outcomes for neuromuscular disease

- patients with respiratory tract infections. *Am J Phys Med Rehabil*. 2005;84:83–8.
- Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200:e45–67.
- McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al., ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2012;33:1787–847.
- Vianello A, Bevilacqua M, Arcaro G, Gallan F, Serra E. Non-invasive ventilatory approach to treatment of acute respiratory failure in neuromuscular disorders. A comparison with endotracheal intubation. *Intensive Care Med*. 2000;26:384–90.
- Servera E, Sancho J, Zafra MJ, Catalá A, Vergara P, Marín J. Alternatives to endotracheal intubation for patients with neuromuscular diseases. *Am J Phys Med Rehabil*. 2005;84:851–7.
- Flandreau G, Bourdin G, Leray V, Bayle F, Wallet F, Delannoy B, et al. Management and long-term outcome of patients with chronic neuromuscular disease admitted to the intensive care unit for acute respiratory failure: a single-center retrospective study. *Respir Care*. 2011;56:953–60.
- Chen TH, Liang WC, Chen IC, Liu YC, Hsu JH, Jong YJ. Combined noninvasive ventilation and mechanical insufflator-exsufflator for acute respiratory failure in patients with neuromuscular disease: effectiveness and outcome predictors. *Ther Adv Respir Dis*. 2019;13, 1753466619875928.
- Crescimanno G, Marone O, Vianello A. Efficacy and comfort of volume-guaranteed pressure support in patients with chronic ventilatory failure of neuromuscular origin. *Respirology*. 2011;16:672–9.
- Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovski T, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. *Am J Respir Crit Care Med*. 2004;170:456–65.
- Chatwin M, Toussaint M, Gonçalves MR. Airway clearance techniques in neuromuscular disorders: a state of the art review. *Respir Med*. 2018;136:98–110.
- Deo P, Bach JR. Noninvasive ventilatory support to reverse weight loss in Duchenne muscular dystrophy: a case series. *Pulmonology*. 2019;25:79–82.
- Chiou M, Bach JR, Saporito LR, Albert O. Quantitation of oxygen-induced hypercapnia in respiratory pump failure. *Rev Port Pneumol*. 2016;22:262–5.

Andrea Vianello<sup>a,\*</sup>, Giovanna Arcaro<sup>a</sup>, Gabriella Guarnieri<sup>a</sup>, Andi Sukthi<sup>a</sup>, Beatrice Molena<sup>a</sup>, Cristian Turato<sup>b</sup>, Fausto Braccioni<sup>a</sup>, Federico Gallan<sup>a</sup>, Francesca Lugato<sup>a</sup>, Martina Turrin<sup>a</sup>, Luca Bello<sup>c</sup>, Paolo Navalesi<sup>d</sup>

<sup>a</sup> Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy

<sup>b</sup> Department of Molecular Medicine, University of Pavia, Pavia, Italy

<sup>c</sup> Department of Neurosciences DNS University of Padova, Padova, Italy

<sup>d</sup> Department of Medicine DIMED, University of Padova, Padova, Italy

\* Corresponding author.

E-mail address: andrea.vianello@aopd.veneto.it (A. Vianello).

<https://doi.org/10.1016/j.arbres.2021.01.015>

0300-2896/ © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Síndrome de absceso hepático y bronconeumonía por *Klebsiella pneumoniae* hipermucoviscosa

### Liver Abscess Syndrome and Hypermucoviscous *Klebsiella pneumoniae* Bronchopneumonia

Estimado Director:

*Klebsiella pneumoniae* es una bacteria gram negativa que forma parte de la flora intestinal de personas sanas, causante raras veces

de infección extrahospitalaria en pacientes con factores de riesgo, y con mayor frecuencia de infecciones nosocomiales urinarias y respiratorias. En 1986 Liu et al. describieron un nuevo síndrome causado por *Klebsiella pneumoniae*, consistente en un absceso hepático asociado a endoftalmítis séptica, cuadro grave e invasivo causado por serotipos capsulares K1 o K2, asociada a un fenotipo de hipermucoviscosidad e hipervirulencia denominado síndrome de absceso hepático (SAHK)<sup>1</sup>. En 2004 Fang et al. identificaron el nuevo gen *magA* en aislamientos de un nuevo microorganismo hipervirulento del SAHK, cuya característica principal es causar infección grave en individuos jóvenes e inmunocompetentes<sup>2</sup>. Presentamos

